Kiniksa Pharmaceuticals International, plc
KNSA
Classifica tra le azioni
#2964
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company,... Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis. It also develops KPL-387, an investigational and fully human immunoglobulin G2 monoclonal antibody, which is Phase 2/3 clinical trial for the treatment of recurrent pericarditis; and KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody, which is in pre-clinical stage. The company was formerly known as Kiniksa Pharmaceuticals, Ltd. and changed its name to Kiniksa Pharmaceuticals International, plc in June 2024. Kiniksa Pharmaceuticals International, plc was incorporated in 2015 and is based in London, the United Kingdom.
Prezzo delle azioni
$79.61
Ultima sincronizzazione: 2026-10-19
Capitalizzazione di mercato
$6.21B
Variazione (1 giorno)
1.30%
Variazione (1 anno)
104.18%
Paese
GB
Scambia Kiniksa Pharmaceuticals International, plc (KNSA)
Categoria
Healthcare
Utile per Kiniksa Pharmaceuticals International, plc (KNSA)
Utile nel Jun 2026 TTM: $114.25M
Secondo gli ultimi rapporti finanziari di Kiniksa Pharmaceuticals International, plc, gli utili attuali della società sono $114.25M. Nel 2023, la società ha registrato un utile di $-16.65M, una diminuzione rispetto a agli utili del 2022, che erano di $11.03M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Kiniksa Pharmaceuticals International, plc dal 2016 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $114.25M | -416.03% |
| 2024 | $-36.15M | 117.10% |
| 2023 | $-16.65M | -251.02% |
| 2022 | $11.03M | -107.04% |
| 2021 | $-156.54M | 0.20% |
| 2020 | $-156.23M | -4.69% |
| 2019 | $-163.91M | 58.46% |
| 2018 | $-103.44M | 59.46% |
| 2017 | $-64.87M | 171.01% |
| 2016 | $-23.94M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $1.35B | 1,081.48% |
US
|
|
| - | - |
SE
|
|
| - | - |
FR
|
|
| - | - |
IT
|
|
| $1.21B | 954.75% |
HK
|
